LivaNova PLC Lifts Guidance After Strong Q1 Call

LivaNova PLC ((LIVN)) has held its Q1 earnings call. Read on for the main highlights of the call.

LivaNova PLC’s latest earnings call struck a notably upbeat tone, with management highlighting broad-based revenue growth, upgraded guidance, and key regulatory wins, even as they acknowledged near-term pressures on cash flow and margins. Executives framed higher capex, supply constraints, and reimbursement uncertainty as deliberate investments and manageable risks against what they see as strong operational momentum.

Top-Line Growth and Upgraded 2026 Revenue Guidance

LivaNova reported Q1 2026 revenue of $362 million, up 11% year over year on a constant-currency basis, underscoring solid demand across its portfolio. Management responded by lifting full-year 2026 revenue growth guidance to 7%–8%, from 6%–7%, signaling increased confidence in the company’s ability to sustain this pace.

Cardiopulmonary Segment Strength

The cardiopulmonary segment was a standout, generating $209 million in Q1 revenue, up 14% versus last year, driven by strong heart-lung machine and consumables sales. Reflecting this momentum, LivaNova raised its full-year cardiopulmonary revenue growth outlook to 8.5%–9.5%, up from 7%–8%, positioning the business as a core earnings engine.

Essenz Upgrade Momentum and Manufacturing Upside

Management emphasized the rapid adoption of the Essenz platform, now expected to account for about 80% of annual heart-lung machine placements in 2026 versus roughly 55% in 2025. To meet demand, the company plans to boost manufacturing output at a low double-digit rate in 2026 and bring a new oxygenator line online in the second half, which should ease capacity bottlenecks.

Epilepsy Business Acceleration and Reimbursement Win

Epilepsy revenue grew 8% year over year, with Europe and the rest of the world up 12% and the U.S. up 7%, reflecting broad geographic strength. A major catalyst came from U.S. Medicare, which sharply increased outpatient payments for VNS therapy from January, prompting LivaNova to raise epilepsy growth guidance to 6%–7% from 5.5%–6.5%.

Regulatory and Clinical Milestones in OSA

In obstructive sleep apnea, LivaNova secured FDA approval for its aura6000 system, which management highlighted as the first HGNS device cleared without a key contraindication label. Full 12-month results from the OSPREY randomized trial, published in a leading medical journal, showed meaningful and sustained clinical benefits, bolstering the therapy’s credibility ahead of commercialization.

PolySync Efficacy and Clinical Differentiation

The company spotlighted its PolySync titration algorithm, which converted more than half of previously nonresponding OSPREY patients into responders. After applying PolySync, the cumulative responder rate approached about 80%, giving LivaNova a potential competitive edge in HGNS as it prepares to enter a crowded but fast-growing market.

Improved Profitability Metrics and EPS Upgrade

Adjusted operating income rose to $71 million in Q1 from $65 million a year ago, with an operating margin around 20% and a full-year target range of 20%–21%. Adjusted diluted EPS improved to $0.98 from $0.88, and the company raised its 2026 EPS guidance to $4.20–$4.30, implying roughly 9% growth at the midpoint.

Balance Sheet Improvements and Debt Reduction

LivaNova ended Q1 with $540 million of cash and total debt of $288 million, down from $377 million at year-end 2025, after an early repayment of $98 million. Management framed the lower leverage as a strategic move that strengthens the balance sheet and provides flexibility, even though it contributed to the quarter’s reduced cash balance.

Adjusted Free Cash Flow and Cash Decrease in Q1

Adjusted free cash flow dipped to $4 million in Q1 from $20 million a year earlier, with cash falling from $636 million to $540 million. The company attributed the decline to early debt paydown, higher capital expenditures, and working capital build, stressing these are timing and investment-related effects rather than signs of weakening fundamentals.

Higher R&D and SG&A Dollars

Adjusted R&D spending increased to $47 million, or 13% of revenue, from $38 million, reflecting heavier investment in the OSA franchise and other growth programs. SG&A rose to $129 million from $116 million, yet improved to 36% of revenue from 37%, suggesting LivaNova is scaling commercial infrastructure while still gaining efficiency.

Adjusted Gross Margin Slightly Lower

Adjusted gross margin edged down to 68% of net revenue from 69% in the prior-year quarter, as volume growth and pricing were offset by unfavorable currency and product mix. Management acknowledged the modest compression but portrayed it as manageable in the context of the company’s overall margin framework and pricing power.

Supply Constraints and Backorder Environment Persist

Demand for oxygenators continues to exceed LivaNova’s ability to supply, keeping the business in a backorder environment despite some improvement in third-party components. Executives cautioned that while supplier performance is getting better, further progress is needed before the company can capture upside beyond what is already baked into guidance.

Market Access and Reimbursement Uncertainties

The company noted ongoing uncertainty around reimbursement and coding for HGNS, which could affect the timing of the aura6000 rollout in the U.S. It is also in active discussions with authorities regarding difficult-to-treat depression reimbursement, but management stressed that timing and outcomes remain uncertain and are not fully reflected in forecasts.

External Macro and One-Time Impacts

LivaNova estimated a roughly $5 million full-year impact on adjusted operating income from Middle East conflict-related shipping, logistics, and fuel costs. Tariff effects are expected to be under $5 million on a net basis, and Q1 profitability was unusually low versus run-rate guidance partly due to payout of previously accrued short-term incentives.

Forward-Looking Guidance and Strategic Outlook

For 2026, the company now guides to 7%–8% constant-currency revenue growth, aided by an expected 1% FX tailwind, with cardiopulmonary up 8.5%–9.5% and epilepsy up 6%–7%. LivaNova also targets a 20%–21% adjusted operating margin, an adjusted tax rate near 23%, adjusted EPS of $4.20–$4.30, free cash flow of $160 million–$180 million, and rising manufacturing output as the Essenz platform gains share.

LivaNova’s earnings call painted a picture of a company leaning into growth, supported by strong cardiopulmonary demand, improving epilepsy economics, and promising OSA data. While cash flow pressure, supply constraints, and reimbursement risks remain on the radar, investors heard a message of disciplined investment, rising guidance, and expanding clinical and regulatory advantages that could underpin further value creation.